JENNIFER A SMITH
Nursing at Infinity Rd, Durham, NC
License number
Florida 9247760
Issued Date
Jun 26, 2006
Effective Date
Jun 26, 2006
Expiration Date
Apr 30, 2018
Category
Health Care
Type
Registered Nurse
Address
Address
211 Infinity Rd, Durham, NC 27712
Phone
(919) 399-4117
Personal information
See more information about JENNIFER A SMITH at radaris.comName
Address
Phone
4802 Hopewood Ct, Graham, NC 27253
4815 Tumbleweed Dr, Greensboro, NC 27407
4838 Burgaw Dr, Fayetteville, NC 28306
4700 Split Rail Dr, Wilmington, NC 28412
11216 Heritage Green Dr, Cornelius, NC 28031
Professional information
Jennifer Smith - Durham, NC
Work:
Thomas Distributing Inc. LLC
Front Office Assistant Keltic Enterprise - Raleigh, NC
Independent Sales Representative Affiliate Computer Services - Cary, NC
Customer Care Specialist
Front Office Assistant Keltic Enterprise - Raleigh, NC
Independent Sales Representative Affiliate Computer Services - Cary, NC
Customer Care Specialist
Education:
Winston Salem State University - Winston-Salem, NC
BS in Music Business
BS in Music Business
Skills:
Skills: Customer Service Great Phone Etiquette Typing 30-35 WPM Microsoft Office Suite; Computer Savvy Excellent Organizational Flexible Ability to handle and control sensitive information
Hppars Activators
US Patent:
7319104, Jan 15, 2008
Filed:
Feb 25, 2003
Appl. No.:
10/505333
Inventors:
Rodolfo Cadilla - Durham NC, US
Brad Richard Henke - Durham NC, US
Guangcheng Kevin Liu - San Diego CA, US
Jennifer Susan Smith - Durham NC, US
Brad Richard Henke - Durham NC, US
Guangcheng Kevin Liu - San Diego CA, US
Jennifer Susan Smith - Durham NC, US
Assignee:
SmithKline Beecham Corporation - Philadelphia PA
International Classification:
A61K 31/505, A61K 31/42, A61K 31/445, A61K 31/425, C07D 239/02
US Classification:
514275, 514324, 514374, 514331, 514365, 544323, 548187, 548235
Abstract:
Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed. In particular methods for treating diseases or conditions associated with one or more of human PPAR alpha, gamma, or delta (“hPPARs”) comprising administration of a therapeutically effective amount of a compound of formula (1), are disclosed.